Immunoglobulin Single Variable Domain Antibody Against RSV Prefusion F Protein

The EPO published patent application EP3313432A1, a new patent grant for an immunoglobulin single variable domain antibody specifically targeting RSV prefusion F protein. The patent names multiple applicants including academic institutions (VIB VZW, Universiteit Gent, Dartmouth College) and government entities (US Department of Health and Human Services). IPC classifications indicate therapeutic applications under A61P 31/14 (antiviral agents).

For pharmaceutical companies and biotechnology firms developing RSV therapeutics, this patent establishes intellectual property rights that may affect freedom-to-operate analyses for competing RSV antibody or vaccine products. Developers of RSV treatments should assess whether their technologies potentially infringe this granted patent and consider licensing negotiations with the patent holders.